89bio Inc (ETNB)
8.61
-0.36
(-4.01%)
USD |
NASDAQ |
May 17, 16:00
8.61
0.00 (0.00%)
After-Hours: 20:00
89bio Cash from Investing (Quarterly): -79.90M for March 31, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | -79.90M |
December 31, 2023 | -63.64M |
September 30, 2023 | 38.33M |
June 30, 2023 | -101.81M |
March 31, 2023 | 4.106M |
December 31, 2022 | -11.06M |
September 30, 2022 | -42.06M |
June 30, 2022 | -7.596M |
March 31, 2022 | 26.77M |
December 31, 2021 | 19.09M |
September 30, 2021 | 17.36M |
Date | Value |
---|---|
June 30, 2021 | -13.88M |
March 31, 2021 | -15.41M |
December 31, 2020 | -29.03M |
September 30, 2020 | -72.00M |
June 30, 2020 | -5.744M |
March 31, 2020 | -0.061M |
December 31, 2019 | -0.111M |
September 30, 2019 | -0.008M |
June 30, 2019 | -0.018M |
March 31, 2019 | -0.002M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-101.81M
Minimum
Jun 2023
38.33M
Maximum
Sep 2023
-16.83M
Average
-6.67M
Median
Cash from Investing (Quarterly) Benchmarks
Akero Therapeutics Inc | 57.85M |
Madrigal Pharmaceuticals Inc | 98.05M |
Viking Therapeutics Inc | -459.79M |
Galectin Therapeutics Inc | -- |
Terns Pharmaceuticals Inc | 7.997M |
Cash from Investing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | -39.72M |
Cash from Financing (Quarterly) | 21.03M |
Free Cash Flow | -138.82M |
Free Cash Flow Per Share (Quarterly) | -0.4144 |
Free Cash Flow Yield | -19.67% |